A combination of HER-2 status and the St. Gallen classification provides useful information on prognosis in lymph node-negative breast carcinoma

Cancer

Volumn 101, Issue 11, 2004, Pages 2516-2522

  Sun, Jong Mu ^a   Han, Wonshik ^a   Im, Seock Ah ^a   Kim, Tae You ^a,b   In, Ae Park ^a   Noh, Dong Young ^a   Dae, Seog Heo ^a   Bang, Yung Jue ^a   Kuk, Jin Choe ^a   Noe, Kyeong Kim ^a  

^a Seoul National University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

Adjuvant chemotherapy; Biologic marker; Breast carcinoma; HER 2; Lymph node negative; Prognosis; St. Gallen classification

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE NEGATIVE BREAST CARCINOMA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; ST. GALLEN CLASSIFICATION; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; MIDDLE AGED; NEOPLASM STAGING; ODDS RATIO; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; UP-REGULATION;

EID: 8844232551     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20665     Document Type: Review

References (28)

1. Wallgren A, Bonetti M, Gelber RD, et al. Risk factors for locoregional recurrence among breast cancer patients: results from international breast cancer study group trial I through VII. J Clin Oncol. 2003;21:1205-1213.
2. Kuru B, Camlibel M, Ali Gulcelik M, Alagol H. Prognostic factors affecting survival and disease-free survival in lymph node-negative breast carcinomas. J Surg Oncol. 2003;83:167-172.
3. Goldhirsch A, Wood WC, Gelber RD, et al. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol. 2003;21:3357-3365.
4. Iwamoto E, Fukutomi, T, Akashi-Tanaka S. Validation and problems of St. Gallen recommendation of adjuvant therapy for node-negative invasive breast cancer in Japanese patients. Jpn J Clin Oncol. 2001;31:259-262.
5. Boyages, J, Chua B, Taylor R, et al. Use of the St. Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy. Br J Surg. 2002;89:789-796.
6. van de vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347:1999-2009.
7. Ahr A, Karn T, Solbach C, et al. Identification of high risk breast-cancer patients by gene expression profiling. Lancet. 2002;359:131-132.
8. Coradini D, Daidone MG.. Biomolecular prognostic factors in breast cancer. Curr Opin Obstet Gynecol. 2004;16:49-55.
9. Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002;235:10-26.
10. Kallioniemi A. Molecular signature of breast cancer-predicting the future. N Engl J Med. 2002;347:2067-2068.
11. Bull SB, Ozcelik H, Pinnaduwage D, et al. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol. 2004;22:86-96.
12. Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol. 2001;12:23-28.
13. Swede H, Moysich KB, Winston JS, et al. Variation of the prognostic significance of HER-2 expression in breat cancer according to tumor size. Breast J. 2003;9:98-105.
14. Reed W, Hannisdal E, Bochler PJ, et al. The prognostic value of p53 and c-erb-B2 immunostaining is overrated for patients with lymph node negative breast carcinoma. Cancer. 2000;88:804-813.
15. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182.
16. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
17. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991;51: 944-948.
18. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4332-4337.
19. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol. 1993;11:1936-1942.
20. Bianchi S, Paglierani M, Zampi G, et al. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer. 1993;67:625-629.
21. Singh L, Wilson AJ, Baum M, et al. The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial. Br J Cancer. 1988;57:612-614.
22. Lebeau A, Deimling D, Kaltz C, et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001;19:354-363.
23. Palazzi M, De Tomasi D, D'Affronto C, et al. Are international guidelines for the prescription of adjuvant treatment for early breast cancer followed in clinical practice? Results of a population-based study on 1547 patients. Tumori. 2002;88:503-506.
24. Zemzoum I, Kates RE, Ross JS, et al. Invasion factor uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol. 2003;21:1022-1028.
25. Volpi A, Nanni O, De Paola F, et al. HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol. 2003;21:2708-2712.
26. Allred DC, Clark GM, Tondon AK, et al. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol. 1992;10:599-605.
27. Carlomagno C, Perrone F, Gallo C, et al. C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14:2702-2708.
28. Martin M, Villar A, Sole-Calvo A, et al. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol. 2003;14:833-842.